Vunakizumab
Cross-source consensus on Vunakizumab from 1 sources and 5 claims.
1 sources · 5 claims
How it works
Dosage & preparation
Background
Where it comes from
Highlighted claims
- Vunakizumab is a recombinant humanized monoclonal antibody targeting interleukin-17A. — Efficacy of Vunakizumab in Erosive haNd osteoarthritiS (VENuS): protocol for a multicentre, randomised controlled trial
- In VENuS, vunakizumab is given subcutaneously as 120 mg in 1 mL, while placebo is matched sterile saline. — Efficacy of Vunakizumab in Erosive haNd osteoarthritiS (VENuS): protocol for a multicentre, randomised controlled trial
- Vunakizumab was approved in China in August 2024 for adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. — Efficacy of Vunakizumab in Erosive haNd osteoarthritiS (VENuS): protocol for a multicentre, randomised controlled trial
- Participants receive vunakizumab or placebo every 4 weeks for 24 weeks, with more frequent dosing in the first 4 weeks. — Efficacy of Vunakizumab in Erosive haNd osteoarthritiS (VENuS): protocol for a multicentre, randomised controlled trial
- Vunakizumab is being developed by Suzhou Suncadia Biopharmaceutical for systemic treatment of autoimmune diseases related to the IL-17 pathway. — Efficacy of Vunakizumab in Erosive haNd osteoarthritiS (VENuS): protocol for a multicentre, randomised controlled trial